News
2d
Zacks Investment Research on MSNRegeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...
Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...
Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...
Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...
The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...
The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.
The American Lung Association is launching a new campaign to support and empower individuals living with chronic ...
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results